Evaluation of Baseline and Interim-Therapy PET Features for Prognostication in High-Risk Pediatric Hodgkin Lymphoma: A Retrospective Analysis of the AHOD1331 Trial
Authors:
- 18 June 2026
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
Abstract
This study aimed to evaluate the prognostic value of conventional and advanced PET metrics for predicting progression-free survival in high-risk pediatric Hodgkin lymphoma (HL), using data from the Children's Oncology Group AHOD1331 trial. Methods: This retrospective analysis included 558 patients from 150 institutions. Conventional PET metrics and radiomics features were extracted from both baseline and interim-therapy PET images. Clinical variables, including demographic characteristics and common risk factors, were also considered. A standardized outcome-modeling pipeline was developed, comprising feature selection and penalized Cox regression with elastic net regularization (CoxNet). Models were trained and evaluated using nested cross-validation stratified by institution, ensuring consistent external testing. We investigated whether conventional PET metrics added prognostic value beyond clinical variables and whether radiomics or interim PET-derived features offered further benefit. Additionally, we compared the prognostic performance of features extracted from automated deep learning (DL) segmentations against those derived from physician annotations. Model performance was assessed using the concordance index (C-index). Results: Among all types of features, the CoxNet model using conventional baseline PET metrics achieved the highest performance (C-index, 0.72 ± 0.01), significantly outperforming the clinical model (C-index, 0.65 ± 0.01). Neither the inclusion of radiomics features nor interim PET-derived features improved performance. Models using DL-generated segmentations achieved comparable prognostic accuracy (C-index, 0.72 ± 0.01) to those using physician-based segmentations. Conclusion: Quantitative PET features provided significant prognostic improvements over clinical variables. Furthermore, DL-based segmentation offered a promising approach for automating feature extraction, supporting more effective risk stratification in pediatric HL.Keywords
This publication has 21 references indexed in Scilit:
- Automatic Quantification of Serial PET/CT Images for Pediatric Hodgkin Lymphoma Using a Longitudinally Aware Segmentation NetworkRadiology: Artificial Intelligence, 2025
- TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methodsBMJ, 2024
- Prognostic Value of Baseline Tumor Burden and Tumor Dissemination Extracted From 18F-FDG PET/CT in a Cohort of Adult Patients With Early or Advanced Hodgkin LymphomaClinical Nuclear Medicine, 2023
- Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group studyBritish Journal of Haematology, 2023
- Joint EANM/SNMMI guideline on radiomics in nuclear medicineEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s LymphomaNew England Journal of Medicine, 2022
- Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphomaScientific Reports, 2021
- Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology GroupBritish Journal of Haematology, 2019
- qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Pediatric lymphoma: metabolic tumor burden as a quantitative index for treatment response evaluationAnnals of Nuclear Medicine, 2011